PRO-LAD

PRO-LAD
Systematic (IUPAC) name

(8β)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide
Clinical data
Legal status	Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.
Routes of administration	Oral
Pharmacokinetic data
Metabolism	hepatic
Excretion	renal
Identifiers
CAS Registry Number	65527-63-1^Y
PubChem	CID 44457803
ChemSpider	21106361^Y
ChEMBL	CHEMBL22258^Y
Synonyms	PRO-LAD, 6-propyl- 6-nor- Lysergic acid diethylamide, (6aR,9R)- N,N- diethyl- 7-propyl- 4,6,6a,7,8,9- hexahydroindolo- [4,3-fg] quinoline- 9- carboxamide
Chemical data
Formula	C₂₂H₂₉N₃O
Molecular mass	351.50 g/mol
SMILES CCN(CC)C(=O)[C@@H]2/C=C1/c3cccc4ncc(C[C@H]1N(C2)CCC)c34
InChI InChI=1S/C22H29N3O/c1-4-10-25-14-16(22(26)24(5-2)6-3)11-18-17-8-7-9-19-21(17)15(13-23-19)12-20(18)25/h7-9,11,13,16,20,23H,4-6,10,12,14H2,1-3H3/t16-,20-/m1/s1 ^Y Key:HZKYLVLOBYNKKM-OXQOHEQNSA-N ^Y
Y (what is this?) (verify)

PRO-LAD is an analogue of LSD. It is described by Alexander Shulgin in the book TiHKAL. PRO-LAD is a psychedelic drug similar to LSD, and is around as potent as LSD itself with an active dose reported at between 100 and 200 micrograms.^[1]

Legal Status

On June 10th 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that LSZ be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.^[2] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.

Literature

Andrew J. Hoffman, David E. Nichols: Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. In: Journal of Medicinal Chemistry. 28, 1985, p. 1252–1255, doi:10.1021/jm00147a022.
T. Niwaguchi, Y. Nakahara, H. Ishii: Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. In: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. Vol. 96, No. 5, May 1976, p. 673–678, PMID 987200.
Robert C. Pfaff, Xuemei Huang, Danuta Marona-Lewicka, Robert Oberlender and David E. Nichols: Lysergamides Revisited. In: NIDA Research Monograph 146: Hallucinogens: An Update. p. 52, 1994, United States Department of Health and Human Services.

References

↑ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428.
↑ ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines". UK Home Office. p. 12. Retrieved 10 June 2014.

External links

Drugs mentioned in TiHKAL

Hallucinogens

Psychedelics
5-HT_2AR agonists

Lysergamides	AL-LAD ALD-52 BU-LAD IP-LAD Diallyllysergamide Dimethyllysergamide Ergometrine ETH-LAD LAE-32 LPD-824 LSA LSD LSD-Pip LSH LSM-775 2-Butyllysergamide LSZ 3-Pentyllysergamide Methylergometrine Methylisopropyllysergamide Methysergide MLD-41 PARGY-LAD PRO-LAD

Phenethylamines	Aleph 2-Methyl-MDA 2C-B 2C-B-AN 2C-B-Dragonfly 2C-B-FLY 2CB-Ind βk-2C-B 2C-C 2C-C-FLY 2C-CP 25C-NBOMe 25CN-NBOH 25CN-NBOMe 25D-NBOMe 2C-D 2C-D-FLY 2C-E 2C-E-FLY 25E-NBOMe 2C-EF 2C-F 25F-NBOMe 2C-G 25G-NBOMe 25H-NBOMe 2C-I βk-2C-I 2C-iP 2C-I-FLY 2C-N 25N-NBOMe 2C-O 2C-O-4 2C-P 2C-T 2C-T-2 2C-T-3 2C-T-4 25T4-NBOMe 2C-T-7 2C-T-7-FLY 25T7-NBOH 2C-T-8 2C-T-13 2C-T-15 2C-T-16 2C-T-17 2C-T-19 2C-T-21 2C-T-21.5 2C-T-22 2C-T-27 2C-T-28 2C-TFE 2C-TFM 25TFM-NBOMe 2C-V 2C-YN 2CBCB-NBOMe 2CBFly-NBOMe 2CD-5EtO 25B-NBOMe 25B-NBOH 25C-NBOH 25I-NBMD 25I-NBOH 25I-NBF 25I-NBOMe 25P-NBOMe 3C-AL 3C-DFE 3C-E 3C-P 3C-TFE 4C-B 4C-D 5-APB 5-APDB 5-APDI 5-Methyl-MDA 6-APB 6-APDB 6-Methyl-MDA Br-DFLY Difluoroescaline Difluoromescaline DESOXY DMBMPP DMMDA DMMDA-2 DOB DOB-FLY DOC DOEF DOET DOF DOI DOM DOM-FLY DON DOPR DOTFM DOYN BOB BOD BMB Escaline Fluoroproscaline Ganesha HOT-2 HOT-7 HOT-17 Isoproscaline Jimscaline Lophophine Macromerine MDA MDEA MDMA Mescaline Mescaline-NBOMe Methallylescaline MMA MMDA MMDA-2 MMDA-3a MMDMA Proscaline TCB-2 TFMFly Trifluoroescaline Trifluoromescaline TMA

Piperazines	pFPP TMFPP mCPP

Tryptamines	1-Me-5-MeO-DiPT 2,N,N-TMT 4,5-DHP-α-MT 4,5-DHP-DMT 4-AcO-DALT 4-AcO-DET 4-AcO-DiPT 4-AcO-DMT 4-AcO-DPT 4-AcO-MiPT 4-HO-5-MeO-DMT 4-HO-DBT 4-HO-DPT 4-HO-MET 4-HO-MPMI 4-HO-MPT 4,N,N-TMT 4-Propionyloxy-DMT 5,6-diBr-DMT 5-AcO-DMT 5-Bromo-DMT 5-Me-MIPT 5-MeO-2,N,N-TMT 5-MeO-4,N,N-TMT 5-MeO-α,N,N-TMT 5-MeO-α-ET 5-MeO-α-MT 5-MeO-DALT 5-MeO-DET 5-MeO-DiPT 5-MeO-DMT 5-MeO-DPT 5-MeO-EiPT 5-MeO-MET 5-MeO-MiPT 5-MeO-MPMI 5-N,N-TMT 7,N,N-TMT α-ET α-MT α,N,N-TMT Aeruginascin Baeocystin Bufotenin DALT DBT DCPT DET DIPT DMT DPT EiPT Ethocin Ethocybin Ibogaine Iprocin MET Miprocin MiPT Norbaeocystin Noribogaine PiPT Psilocin Psilocybin Voacangine

Others	AL-38022A ALPHA Dimemebfe M-ALPHA RH-34

Dissociatives
NMDAR antagonists

Adamantanes	Amantadine Memantine Rimantadine

Arylcyclohexylamines	3-MeO-PCP 4-MeO-PCP Dieticyclidine Esketamine Ethketamine Eticyclidine Gacyclidine Ketamine Methoxetamine Methoxyketamine PCPr Phencyclidine Rolicyclidine Tenocyclidine Tiletamine

Morphinans	Dextrallorphan Dextromethorphan Dextrorphan Racemethorphan Racemorphan

Others	2-MDP 8A-PDHQ Aptiganel Dexoxadrol Diphenidine Dizocilpine Etoxadrol Ibogaine Methoxphenidine Midafotel NEFA Neramexane Nitrous oxide Noribogaine Perzinfotel Remacemide Selfotel Xenon

Deliriants
mAChR antagonists

Miscellaneous

Cannabinoids
CB₁R agonists

Phytocannabinoids	Cannabinol THC (Dronabinol) THCV (Cannabidiol has different mechanism of action)

Synthetic	4-HTMPIPO 5F-PB-22 AB-001 AB-005 A-836,339 AB-CHMINACA AB-FUBINACA AB-PINACA ADB-FUBINACA ADB-PINACA ADBICA AM-630 AM-679 AM-694 AM-1220 AM-1221 AM-1235 AM-1241 AM-1248 AM-2201 AM-2232 AM-2233 APICA APINACA CB-13 CP 47,497 CP 55,244 CP 55,940 DMHP HU-210 HU-308 JWH-007 JWH-015 JWH-018 JWH-019 JWH-030 JWH-073 JWH-081 JWH-098 JWH-116 JWH-122 JWH-149 JWH-167 JWH-182 JWH-193 JWH-198 JWH-200 JWH-203 JWH-210 JWH-250 JWH-251 JWH-398 JWH-424 JTE 7-31 JTE-907 Levonantradol MAM-2201 MDA-19 MN-25 NESS-0327 NESS-040C5 Nabilone Nabitan Org 28611 Parahexyl QUCHIC QUPIC RCS-4 RCS-8 SDB-006 STS-135 THC-O-acetate THC-O-phosphate UR-144 WIN 55,212-2 XLR-11

D₂R agonists

Apomorphine
Aporphine
Bromocriptine
Cabergoline
Lisuride
Memantine
Nuciferine
Pergolide
Piribedil
Pramipexole
Ropinirole
Rotigotine
Also indirect D₂ agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).

GABA_AR agonists

Inhalants
Mixed MOA

Aliphatic hydrocarbons
- Butane
- Gasoline
- Kerosene
- Propane
Aromatic hydrocarbons
- Toluene
Ethers
- Diethyl ether
- Enflurane
Haloalkanes
- Chlorofluorocarbons
- Chloroform

κOR agonists

MAO inhibitors

σR agonists

Others

PRO-LAD

Legal Status

Literature

See also

References

External links